Pamela Munster

Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in ...

A dose limiting toxicity (DLT) will be defined as any predetermined adverse events occurring during Cycle 1 when association to therapy that is part of this study is related or possibly related

Recruiting

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects...

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation ...

Adverse events, serious adverse events, and dose limiting toxicities

Recruiting

9-ING-41 in Patients With Advanced Cancers

The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.

Recruiting

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

ORR is defined as the proportion of patients with either confirmed complete or partial response (as per RECIST version 1.1) as best overall response over the total population.

Recruiting

Study of ORIC-101 in Combination With Anticancer Therapy

RP2D as determined by 3+3 dose escalation design

Recruiting

AO-176 in Multiple Solid Tumor Malignancies

Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.

Recruiting

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies

Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Recruiting